Search

Your search keyword '"Vattemi, Emanuela"' showing total 29 results
Start Over Author "Vattemi, Emanuela"
29 results on '"Vattemi, Emanuela"'

1. Is multidisciplinary management possible in the treatment of lung cancer? A report from three Italian meetings

Author

Franceschini, Davide, Bruni, Alessio, Borghetti, Paolo, Giaj-Levra, Niccolò, Ramella, Sara, Buffoni, Lucio, Badellino, Serena, Andolina, Maria, Comin, Camilla, Vattemi, Emanuela, Bezzi, Michela, Trovò, Marco, Passaro, Antonio, Bearz, Alessandra, Chiari, Rita, Tindara, Franchina, Ferrari, Katia, Piperno, Gaia, Filippi, Andrea Riccardo, Genovesi, Domenico, and Scotti, Vieri

Published
2020
Full Text
View/download PDF

2. A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective Study

Author

Gagno, Sara, D’Andrea, Mario Rosario, Mansutti, Mauro, Zanusso, Chiara, Puglisi, Fabio, Dreussi, Eva, Montico, Marcella, Biason, Paola, Cecchin, Erika, Iacono, Donatella, Russo, Stefania, Cinausero, Marika, Saracchini, Silvana, Gasparini, Giampietro, Sartori, Donata, Bari, Mario, Collovà, Elena, Meo, Rosa, Merkabaoui, Ghassan, Spagnoletti, Ilaria, Pellegrino, Arianna, Gianni, Lorenzo, Sandri, Paolo, Cretella, Elisabetta, Vattemi, Emanuela, Rocca, Andrea, Serra, Patrizia, Fabbri, Maria Agnese, Benedetti, Giovanni, Foghini, Laura, Medici, Michele, Basso, Umberto, Amoroso, Vito, Riccardi, Ferdinando, Baldelli, Anna Maria, Clerico, Mario, Bonura, Salvatore, Saggia, Chiara, Innocenti, Federico, and Toffoli, Giuseppe

Published
2019
Full Text
View/download PDF

4. Pretreatment lung immune prognostic index as a biomarker in advanced non-small-cell lung cancer patients receiving first line pembrolizumab

Author

Veccia, Antonello, primary, Sforza, Vincenzo, additional, Vattemi, Emanuela, additional, Inno, Alessandro, additional, Kinspergher, Stefania, additional, Dipasquale, Mariachiara, additional, Gori, Stefania, additional, Morabito, Alessandro, additional, Baldi, Ileana, additional, and Caffo, Orazio, additional

Published
2021
Full Text
View/download PDF

7. Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients

Author

Reale, Maria Lucia, primary, Chiari, Rita, additional, Tiseo, Marcello, additional, Vitiello, Fabiana, additional, Barbieri, Fausto, additional, Cortinovis, Diego, additional, Ceresoli, Giovanni Luca, additional, Finocchiaro, Giovanna, additional, Romano, Gianpiero Diego, additional, Piovano, Pier Luigi, additional, Del Conte, Alessandro, additional, Borra, Gloria, additional, Verderame, Francesco, additional, Scotti, Vieri, additional, Nonnis, Daniela, additional, Galetta, Domenico, additional, Sergi, Concetta, additional, Migliorino, Maria Rita, additional, Tonini, Giuseppe, additional, Cecere, Fabiana, additional, Berardi, Rossana, additional, Pino, Maria Simona, additional, Martelli, Olga, additional, Gelibter, Alain, additional, Carta, Annamaria, additional, Vattemi, Emanuela, additional, Pagano, Maria, additional, Zullo, Alessandro, additional, Ferrari, Silvia, additional, Rossi, Antonio, additional, and Novello, Silvia, additional

Published
2020
Full Text
View/download PDF

8. Is multidisciplinary management possible in the treatment of lung cancer? A report from three Italian meetings

Author

Franceschini, Davide, primary, Bruni, Alessio, additional, Borghetti, Paolo, additional, Giaj-Levra, Niccolò, additional, Ramella, Sara, additional, Buffoni, Lucio, additional, Badellino, Serena, additional, Andolina, Maria, additional, Comin, Camilla, additional, Vattemi, Emanuela, additional, Bezzi, Michela, additional, Trovò, Marco, additional, Passaro, Antonio, additional, Bearz, Alessandra, additional, Chiari, Rita, additional, Tindara, Franchina, additional, Ferrari, Katia, additional, Piperno, Gaia, additional, Filippi, Andrea Riccardo, additional, Genovesi, Domenico, additional, and Scotti, Vieri, additional

Published
2019
Full Text
View/download PDF

11. Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial

Author

Platania, Marco, primary, Pasini, Felice, additional, Porcu, Luca, additional, Boeri, Mattia, additional, Verderame, Francesco, additional, Modena, Yasmina, additional, Del Conte, Alessandro, additional, Nichetti, Federico, additional, Garassino, Marina Chiara, additional, Martinetti, Antonia, additional, Sottotetti, Elisa, additional, Cavanna, Luigi, additional, Vattemi, Emanuela, additional, Pozzessere, Daniele, additional, Bertolini, Alessandro, additional, Irtelli, Luciana, additional, Verri, Carla, additional, Sozzi, Gabriella, additional, Proto, Claudia, additional, Pastorino, Ugo, additional, Torri, Valter, additional, Fraccon, Anna Paola, additional, Spinnato, Francesca, additional, Signorelli, Diego, additional, Lo Russo, Giuseppe, additional, Tuzi, Alessandro, additional, Gallucci, Rosaria, additional, Cinieri, Saverio, additional, Mencoboni, Manlio, additional, Antonelli, Paola, additional, Giacomelli, Luca, additional, and de Braud, Filippo, additional

Published
2019
Full Text
View/download PDF

12. A randomized phase II trial of maintenance oral metronomic vinorelbine versus close observation in advanced non-small cell lung cancer (NSCLC) following platinum-based chemotherapy: MA.NI.LA. trial.

Author

Platania, Marco, primary, Nichetti, Federico, additional, Porcu, Luca, additional, Pasini, Felice, additional, Boeri, Mattia, additional, Modena, Yasmina, additional, Del Conte, Alessandro, additional, Martinetti, Antonia, additional, Sottotetti, Elisa, additional, Pozzessere, Daniele, additional, Vattemi, Emanuela, additional, Verderame, Francesco, additional, Cavanna, Luigi, additional, Fraccon, Anna Paola, additional, Formisano, Barbara, additional, Gallucci, Rosaria, additional, Lo Russo, Giuseppe, additional, Torri, Valter, additional, and De Braud, Filippo G., additional

Published
2018
Full Text
View/download PDF

17. Genetic polymorphisms of EGF 5'-UTR in patients with glioma: A possible predictive marker of outcome.

Author

Vattemi, Emanuela, primary, Cipollini, Giovanna, additional, Dealis, Cristina, additional, Rossi, Lorena, additional, Baier, Susanne, additional, Cretella, Elisabetta, additional, Di Meglio, Giovanni, additional, Sini, Valentina, additional, Lusso, Maria Rita, additional, Ruda, Roberta, additional, Petric, Marija, additional, and Graiff, Claudio, additional

Published
2013
Full Text
View/download PDF

18. Targeted therapies (TT) in metastatic renal cell carcinoma (mRCC): An Italian survey of 902 pts.

Author

Pasini, Felice, primary, Fraccon, Anna Paola, additional, Barile, Carmen, additional, Sacco, Cosimo, additional, Sava, Teodoro, additional, Valduga, Francesco, additional, Basso, Umberto, additional, Vattemi, Emanuela, additional, Rosti, Giovanni, additional, Durante, Emilia, additional, Nicodemo, Maurizio, additional, Lo Re, Giovanni, additional, Cengarle, Rita, additional, Bertocchi, Paola, additional, Bernardi, Daniele, additional, Sartori, Donata, additional, Donati, Donatella, additional, Pegoraro, Cristina, additional, Inno, Alessandro, additional, and Bassan, Franco, additional

Published
2013
Full Text
View/download PDF

20. Intrathecal liposomal cytarabine in combination with temozolomide in low-grade oligoastrocytoma with leptomeningeal dissemination

Author

Passarin, Maria Grazia, primary, Moretto, Giuseppe, additional, Musso, Anna Maria, additional, Ottaviani, Sarah, additional, Masotto, Barbara, additional, Ghimenton, Claudio, additional, Iuzzolino, Paolo, additional, Buffone, Ebba, additional, Rudà, Roberta, additional, Soffietti, Riccardo, additional, Vattemi, Emanuela, additional, and Pedersini, Rebecca, additional

Published
2009
Full Text
View/download PDF

25. A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective Study

Author

Andrea Rocca, Mario D'Andrea, Vito Amoroso, Anna Maria Baldelli, Elisabetta Cretella, Chiara Saggia, Ilaria Spagnoletti, Marcella Montico, Stefania Russo, Rosa Meo, Elena Collovà, Emanuela Vattemi, M. Bari, Eva Dreussi, Ferdinando Riccardi, Umberto Basso, Marika Cinausero, Chiara Zanusso, Michele Medici, Maria Agnese Fabbri, Fabio Puglisi, Donatella Iacono, Lorenzo Gianni, Patrizia Serra, Sara Gagno, Mauro Mansutti, Donata Sartori, Giampietro Gasparini, Laura Foghini, Silvana Saracchini, Erika Cecchin, Paola Biason, Salvatore Bonura, Mario Clerico, Arianna Pellegrino, Ghassan Merkabaoui, Giovanni Benedetti, Giuseppe Toffoli, Paolo Sandri, Federico Innocenti, Gagno, Sara, D'Andrea, Mario Rosario, Mansutti, Mauro, Zanusso, Chiara, Puglisi, Fabio, Dreussi, Eva, Montico, Marcella, Biason, Paola, Cecchin, Erika, Iacono, Donatella, Russo, Stefania, Cinausero, Marika, Saracchini, Silvana, Gasparini, Giampietro, Sartori, Donata, Bari, Mario, Collovà, Elena, Meo, Rosa, Merkabaoui, Ghassan, Spagnoletti, Ilaria, Pellegrino, Arianna, Gianni, Lorenzo, Sandri, Paolo, Cretella, Elisabetta, Vattemi, Emanuela, Rocca, Andrea, Serra, Patrizia, Fabbri, Maria Agnese, Benedetti, Giovanni, Foghini, Laura, Medici, Michele, Basso, Umberto, Amoroso, Vito, Riccardi, Ferdinando, Baldelli, Anna Maria, Clerico, Mario, Bonura, Salvatore, Saggia, Chiara, Innocenti, Federico, and Toffoli, Giuseppe

Subjects
Male, 0301 basic medicine, Oncology, Cancer Research, DNA Repair, Survival, medicine.medical_treatment, chemistry.chemical_compound, 0302 clinical medicine, Exemestane, Medicine, Prospective Studies, Prospective cohort study, Aged, 80 and over, Framingham Risk Score, Aromatase Inhibitors, Hazard ratio, Middle Aged, Metastatic breast cancer, Receptors, Estrogen, 030220 oncology & carcinogenesis, Female, Advanced breast cancer, Signal Transduction, Adult, Risk, medicine.medical_specialty, Antineoplastic Agents, Hormonal, Breast Neoplasms, 03 medical and health sciences, Breast cancer, Aromatase inhibitor, Hormone therapy, Polymorphisms, Internal medicine, Biomarkers, Tumor, Humans, Polymorphism, Aged, Polymorphism, Genetic, business.industry, Proportional hazards model, Reproducibility of Results, medicine.disease, Survival Analysis, Androstadienes, 030104 developmental biology, chemistry, business
Abstract

Currently there are no reliable biomarkers to predict outcome of exemestane treatment. We designed a prospective study to investigate whether constitutive genetic background might affect response to therapy. In a population of 302 advanced breast cancer patients treated with exemestane we showed that a 5-polymorphism-based genetic score could be used to identify patients with different risks of progression and death.Introduction: Approximately 50% of locally advanced or metastatic breast cancer (MBC) patients treated with first-line exemestane do not show objective response and currently there are no reliable biomarkers to predict the outcome of patients using this therapy. The constitutive genetic background might be responsible for differences in the outcome of exemestane-treated patients. We designed a prospective study to investigate the role of germ line polymorphisms as biomarkers of survival. Patients and Methods: Three hundred two locally advanced or MBC patients treated with first-line exemestane were genotyped for 74 germ line polymorphisms in 39 candidate genes involved in drug activity, hormone balance, DNA replication and repair, and cell signaling pathways. Associations with progression-free survival (PFS) and overall survival (OS) were tested with multivariate Cox regression. Bootstrap resampling was used as an internal assessment of results reproducibility. Results: Cytochrome P450 19A1-rs10046TC/CC, solute carrier organic anion transporter 1B1-rs4149056TT, adenosine triphosphate binding cassette subfamily G member 2-rs2046134GG, fibroblast growth factor receptor-4-rs351855TT, and X-ray repair cross complementing 3-rs861539TT were significantly associated with PFS and then combined into a risk score (0-1, 2, 3, or 4-6 risk points). Patients with the highest risk score (4-6 risk points) compared with ones with the lowest score (0-1 risk points) had a median PFS of 10 months versus 26.3 months (adjusted hazard ratio [AdjHR], 3.12 [95% confidence interval (CI), 2.18-4.48]; P < .001) and a median OS of 38.9 months versus 63.0 months (AdjHR, 2.41 [95% CI, 1.22-4.79], P = .012), respectively. Conclusion: In this study we defined a score including 5 polymorphisms to stratify patients for PFS and OS. This score, if validated, might be translated to personalize locally advanced or MBC patient treatment and management.

Published
2019

26. Impact of the IASLC/ATS/ERS classification in pN0 pulmonary adenocarcinomas: a study with radiological-pathological comparisons and survival analyses.

Author

Ambrosini-Spaltro A, Ruiu A, Seebacher C, Vattemi E, Gentile L, Feil B, Zaraca F, and Carella R

Subjects
Adenocarcinoma mortality, Aged, Aged, 80 and over, Female, Humans, Lung Neoplasms mortality, Lung Neoplasms pathology, Male, Middle Aged, Neoplasm Staging, Proportional Hazards Models, Survival Analysis, Tomography, X-Ray Computed, Adenocarcinoma classification, Adenocarcinoma diagnostic imaging, Lung Neoplasms classification, Lung Neoplasms diagnostic imaging
Abstract

The aim of this study was: (1) to compare the new pathological findings as detected by the IASLC/ATS/ERS classification with the traditional radiological features in pulmonary pN0 adenocarcinomas, (2) to evaluate their prognostic significance on overall survival (OS). A total of 42 surgically resected pN0 pulmonary adenocarcinomas were analyzed. On CT scans, the following radiological data were recorded: sphericity, predominant margins, cavitation and bronchogram, attenuation and percentage of ground glass opacity (GGO). On pathological examination, tumors were categorized according to the IASLC/ATS/ERS classification; Sica score and grade, pathological stage, tumor major axis, pleural invasion, vascular and lymphatic invasion, peritumoral lymphoid infiltration, and cytological features were also determined. Clinical follow up was available in 37 cases (range 1-117 months). Radiologically, 31 solid and 11 semisolid tumors were found. Morphologically, 2 minimally invasive and 40 invasive adenocarcinomas were diagnosed. In radiological-pathological comparisons, (1) the acinar pattern was higher in tumors with solid attenuation and low GGO (p=0.018); (2) the lepidic pattern was more elevated in tumors with high GGO (p=0.012). In multivariate survival analyses with stage, predominant margins on CT scans (p=0.036) and Sica score (p=0.028) significantly affected OS. This study confirms the validity of the new classification of pulmonary adenocarcinomas in radiological-pathological comparisons and underlines the importance of both radiological and pathological findings in correctly identifying their prognostic features., (Copyright © 2013 Elsevier GmbH. All rights reserved.)

Published
2014
Full Text
View/download PDF

27. Adenoviral gene therapy in high-grade malignant glioma.

Author

Pedersini R, Vattemi E, and Claudio PP

Subjects
Animals, Genes, p53, Genetic Vectors, Humans, Inhibitor of Growth Protein 1, Intracellular Signaling Peptides and Proteins genetics, Nuclear Proteins genetics, Oncolytic Virotherapy, Simplexvirus enzymology, Thymidine Kinase genetics, Tumor Suppressor Proteins genetics, Adenoviridae genetics, Brain Neoplasms therapy, Genetic Therapy, Glioma therapy
Abstract

Despite advances in surgical techniques, improvement in radiation treatments and chemotherapy, and the addition of new biological agents to the armamentarium, the median survival of patients with high-grade malignant glioma has changed little over recent decades. However, advances in the fundamental understanding of brain tumor biology suggest that targeting molecular pathways underlying carcinogenesis may provide alternative or additional approaches to glioma treatment. Viruses, particularly adenoviruses, have been critical in the application and development of these molecular approaches. Adenoviruses have been engineered to function as vectors for delivering therapeutic genes for gene therapy, and as direct cytotoxic agents for oncolytic viral therapy. The purpose of this review is to provide a prospective on the use of adenoviruses in high-grade malignant glioma therapy., (Copyright 2010 Prous Science, S.A.U. or its licensors. All rights reserved.)

Published
2010
Full Text
View/download PDF

28. Tumor suppressor genes as cancer therapeutics.

Author

Vattemi E and Claudio PP

Subjects
Animals, Cell Cycle genetics, Cell Cycle physiology, Clinical Trials as Topic, Genetic Therapy trends, Humans, Models, Biological, Tumor Suppressor Proteins genetics, Genetic Therapy methods, Tumor Suppressor Proteins physiology
Abstract

Cancer formation is a multistep process that involves the sequential activation of oncogenes as well as the inactivation of tumor suppressor genes often in the same clone of cells. These genetic changes generate concomitant phenotypic changes in the tumor cells that allow them to continue to survive and expand. Over the past decade a number of genetic alterations in oncogenes and tumor suppressor genes have been identified and extensive research has elucidated their role in cellular growth, differentiation and apoptosis. Targeting tumor suppressor gene pathways is an attractive therapeutic strategy in cancer. This review summarizes the current achievements and future prospects of gene replacement therapy. Methods of gene delivery are described, particularly those that have commonly be used in clinical trials. We discuss efforts to achieve tissue-specific gene delivery and improved efficiency of gene delivery., ((c) 2007 Prous Science. All rights reserved.)

Published
2007
Full Text
View/download PDF

29. Adenoviral gene therapy in head and neck cancer.

Author

Vattemi E and Claudio PP

Subjects
Animals, Antineoplastic Agents therapeutic use, Clinical Trials as Topic, Combined Modality Therapy, Gene Transfer Techniques, Head and Neck Neoplasms genetics, Head and Neck Neoplasms metabolism, Humans, Mutation, Oncolytic Virotherapy, Tumor Suppressor Protein p53 genetics, Tumor Suppressor Protein p53 metabolism, Viral Vaccines, Adenoviridae genetics, Adenoviridae metabolism, Gene Expression Regulation, Neoplastic, Genetic Therapy methods, Genetic Vectors, Head and Neck Neoplasms therapy
Abstract

Despite advances in surgical techniques, improvement in radiation therapy and the addition of new biological agents such as cetuximab to traditional chemotherapy, the median survival of patients with head and neck cancer has changed little over the past few decades. However, recent advances in the fundamental understanding of head and neck cancer biology suggest that targeting molecular pathways underlying carcinogenesis may provide alternative or additional approaches to the treatment of head and neck cancer. Viruses, particularly adenoviruses, have been critical in the application and development of these molecular approaches. Adenoviruses have been engineered to function as vectors for delivering therapeutic genes for gene therapy. The purpose of this review is to provide a prospective on the use of adenoviruses in head and neck cancer therapy by examining clinical trials of adenovirus-mediated p53 gene therapy and by reviewing the application of a promising oncolytic adenovirus, ONYX-015, in head and neck cancer., ((c) 2006 Prous Science. All rights reserved.)

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results